Abstract
NYVAC-based vaccinia virus recombinants expressing the circumsporozoite protein (CSP) were evaluated in the Plasmodium berghei rodent malaria model system. Immunization of mice with a NYVAC-based CSP recombinant elicited a high level of protection (60 to 100%). Protection did not correlate with CS repeat-specific antibody responses and was abrogated by in vivo CD8+ T-cell depletion. Protection was not enhanced by modification of the subcellular localization of CSP. These results suggest the potential of poxvirus-based vectors for the development of vaccine candidates for human malaria.
MeSH terms
-
Animals
-
Antibodies, Protozoan / biosynthesis
-
Humans
-
Immunity, Cellular
-
Malaria / immunology
-
Malaria / prevention & control*
-
Mice
-
Mice, Inbred BALB C
-
Plasmodium berghei / genetics
-
Plasmodium berghei / immunology*
-
Protozoan Proteins / genetics
-
Protozoan Proteins / immunology*
-
Protozoan Vaccines / genetics
-
Protozoan Vaccines / pharmacology*
-
Recombinant Proteins / genetics
-
Recombinant Proteins / immunology
-
T-Lymphocyte Subsets / immunology
-
Vaccines, Attenuated / genetics
-
Vaccines, Attenuated / pharmacology
-
Vaccines, Synthetic / genetics
-
Vaccines, Synthetic / pharmacology*
-
Vaccinia virus / genetics
-
Vaccinia virus / immunology
Substances
-
Antibodies, Protozoan
-
Protozoan Proteins
-
Protozoan Vaccines
-
Recombinant Proteins
-
Vaccines, Attenuated
-
Vaccines, Synthetic
-
circumsporozoite protein, Protozoan